Home Blog

0 15

Patent Number: 8,829,264

Grant date: September 09, 2014
Priority date: January 22, 2002
Estimated expiration date: January 22, 2022
Inventor(s): Hannon; Gregory J. (Huntington, NY), Paddison; Patrick (Seattle, WA), Bernstein; Emily (New York, NY), Caudy; Amy (Toronto, CA), Conklin; Douglas (Niskayuna, NY), Hammond; Scott (Pittsboro, NC)
Assignee(s): Cold Spring Harbor Laboratory (Cold Spring Harbor, NY)
External link: USPTO website

Abstract:

The present invention provides methods for attenuating gene expression in a cell, especially in a mammalian cell, using gene-targeted double stranded RNA (dsRNA), such as a hairpin RNA. The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene).

0 8

Patent Number: 8,828,737

Grant date: September 09, 2014
Priority date: September 17, 2004
Estimated expiration date: September 17, 2024
Inventor(s): Gabriel; Don (Carrboro, NC)
Assignee(s): Invitrox, Inc. (Durham, NC)
External link: USPTO website

Abstract:

Methods for using focused light scattering techniques for the optical sensing of biological particles suspended in a liquid medium are disclosed. The optical sensing enables one to characterize particles size and/or distribution in a given sample. This, in turn, allows one to identify the biological particles, determine their relative particle density, detect particle shedding, and identify particle aggregation. The methods are also useful in screening and optimizing drug candidates, evaluating the efficacy and dosage levels of such drugs, and in personalized medicine applications.

0 8

Patent Number: 8,828,722

Grant date: September 09, 2014
Priority date: September 17, 2004
Estimated expiration date: September 17, 2024
Inventor(s): Dekel; Benjamin (Tel-Aviv, IL)
Assignee(s): Tel HaShomer Medical Research Infrastructure and Services Ltd. (Ramat-Gan, IL)
External link: USPTO website

Abstract:

Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.

0 10

Patent Number: 8,828,720

Grant date: September 09, 2014
Priority date: September 17, 2004
Estimated expiration date: September 17, 2024
Inventor(s): Oh; Steve (Singapore, SG), Reuveny; Shaul (Singapore, SG), Chen; Allen (Singapore, SG)
Assignee(s): Agency for Science, Technology and Research (Connexis, SG)
External link: USPTO website

Abstract:

We disclose a particle comprising a matrix coated thereon and having a positive charge, the particle being of a size to allow aggregation of primate or human stem cells attached thereto. The particle may comprise a substantially elongate, cylindrical or rod shaped particle having a longest dimension of between 50 .mu.m and 400 .mu.m, such as about 200 .mu.m. It may have a cross sectional dimension of between 20 .mu.m and 30 .mu.m. The particle may comprise a substantially compact or spherical shaped particle having a size of between about 20 .mu.m and about 120 .mu.m, for example about 65 .mu.m. We also disclose a method of propagating primate or human stem cells, the method comprising: providing first and second primate or human stem cells attached to first and second respective particles, allowing the first primate or human stem cell to contact the second primate or human stem cell to form an aggregate of cells and culturing the aggregate to propagate the primate or human stem cells for at least one passage. A method of propagating human embryonic stem cells (hESCs) in long term suspension culture using microcarriers coated in Matrigel or hyaluronic acid is also disclosed. We also disclose a method for differentiating stem cells.

0 13

Patent Number: 8,828,681

Grant date: September 09, 2014
Priority date: September 17, 2004
Estimated expiration date: September 17, 2024
Inventor(s): Bell, III; Caleb B. (San Mateo, CA), Bazarov; Alexey (Fremont, CA)
Assignee(s): Bell Biosystems, Inc. (Palo Alto, CA)
External link: USPTO website

Abstract:

The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria.

0 5

Patent Number: 8,828,436

Grant date: September 09, 2014
Priority date: September 17, 2004
Estimated expiration date: September 17, 2024
Inventor(s): Hossainy; Syed (Hayward, CA), Ngo; Michael (San Jose, CA), Trollsas; Mikael (San Jose, CA), Stankus; John (Campbell, CA), Michal; Gene (San Francisco, CA)
Assignee(s): Abbott Cardiovascular Systems Inc. (Santa Clara, CA)
External link: USPTO website

Abstract:

Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.

0 4

Patent Number: 8,828,433

Grant date: September 09, 2014
Priority date: September 17, 2004
Estimated expiration date: September 17, 2024
Inventor(s): Claude; Charles (Flagstaff, AZ), Kwok; Connie (Shoreline, WA), Michal; Gene (San Francisco, CA), Qu; Jihong (Maple Grove, MN), Liao; Sophia (Irvine, CA)
Assignee(s): Advanced Cardiovascular Systems, Inc. (Santa Clara, CA)
External link: USPTO website

Abstract:

Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael’s addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-1-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-1-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.

0 4

Patent Number: 8,828,383

Grant date: September 09, 2014
Priority date: September 17, 2004
Estimated expiration date: September 17, 2024
Inventor(s): Almutairi; Adah (La Jolla, CA), Fomina; Nadezda (San Diego, CA), Sankaranarayanan; Jagadis (San Diego, CA)
Assignee(s): The Regents of the University of California (Oakland, CA)
External link: USPTO website

Abstract:

Compositions are provided in which dendrimers and/or nanoparticles are synthesized with multi-photon responsive elements and self-immolative oligomers. The compositions may be utilized to selectively deliver Payloads within tissue by irradiating the compositions. The compositions may also be used to amplify sensitivity to irradiation.

0 3

Patent Number: 8,828,376

Grant date: September 09, 2014
Priority date: September 17, 2004
Estimated expiration date: September 17, 2024
Inventor(s): Zeitlin; Andy (Basking Ridge, NJ), Pal; Ajai (Bridgewater, NJ)
Assignee(s): Anthrogenesis Corporation (Warren, NJ)
External link: USPTO website

Abstract:

Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and/or compositions comprising placental stem cells.

0 3

Patent Number: 8,828,375

Grant date: September 09, 2014
Priority date: September 17, 2004
Estimated expiration date: September 17, 2024
Inventor(s): Itescu; Silviu (Victoria, AU), Schuster; Michael David (New York, NY)
Assignee(s): Mesoblast, Inc. (New York, NY)
External link: USPTO website

Abstract:

The present invention relates to a method of transplanting haematopoietic precursor cells into a subject in need thereof which involves culturing the haematopoietic precursor cells in the presence of a population of cells enriched for STRO-1.sup.bright cells. The method of the present invention is useful in the treatment of haematological disorders.